Care Beyond Diagnosis and Landrace Bioscience Merge to Revolutionize Bioavailability Solutions with SENDS® Technology
Baltimore, MD – March 13, 2025 – Two industry leaders, Care Beyond Diagnosis LLC and Landrace Bioscience Inc., have merged, creating 11Three, a collaborative new venture aimed at harnessing the power of the revolutionary Solubilized Enhanced Drug Delivery System (SENDS®) technology. SENDS® builds upon the proven advantages of micelle-based delivery systems, incorporating unique, patented features to offer unmatched precision, stability, and therapeutic efficacy. With this technology, 11Three is poised to transform how nutraceutical, pharmaceutical, and other health-related products are developed and utilized.
“11Three combines the expertise and resources of two industry leaders to redefine bioavailability solutions across multiple sectors,” said Patrick Kelly, spokesperson for 11Three. “By working together, we aim to solve longstanding challenges in ingredient delivery, creating products that are more effective, efficient, and accessible.”
SENDS® is a cutting-edge emulsion technology that enhances the bioavailability of active compounds, ensuring they are absorbed more rapidly and effectively by the body. The culmination of 25 years of academic research and industry expertise, the SENDS® platform is a solution to decades-long issues with inconsistent delivery and performance of active ingredients. Engineered for precision, SENDS® allows for the functionalization of micelle structures with ligands and specialized coatings. This ensures drugs are directed towards specific tissues or cells, minimizing systemic side effects. It is this controlled, targeted delivery that enhances safety and effectiveness across therapies.
“With the ability to solubilize diverse drug types, SENDS® is a versatile platform compatible with various therapeutic agents, including hydrophobic small molecules, vitamins, peptides, proteins, nucleic acids, hormones, and anti-inflammatory agents,” said John Dombrowski, MD, Chief Science Officer at 11Three. “Its adaptability allows for applications ranging from oncological therapies to gene and vaccine delivery. Additionally, it holds tremendous potential to advance products in food and beverage, nutraceuticals, topical applications, and agricultural support products.”
“This collaboration signals a new era in health innovation, reinforcing the commitment of Care Beyond Diagnosis and Landrace Bioscience to improving lives through cutting-edge technology,” commented Kelly. “With SENDS® at the heart of what we do, we’re excited to transform how bioavailability challenges are addressed across industries, driving better health outcomes and empowering businesses and consumers alike.”
About 11Three
11Three is dedicated to advancing bioavailability solutions across industries and creating accessible, high-quality solutions in health and wellness. At its core lies the SENDS® technology, which redefines how active ingredients are delivered to consumers, offering unparalleled effectiveness for a wide range of applications. 11Three stems from the philosophy that 1+1=3—a belief that collaboration creates something far greater than the sum of its parts. The company will be headquartered at the University of Maryland BioPark in Baltimore to fully utilize the facility for research, testing and Interdisciplinary collaboration.
For more information on this collaboration and the resulting advancements of SENDS® technology, please contact Patrick Kelly at [email protected].